Citi lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $7 from $9 and keeps a Neutral rating on the shares. The firm sees opportunities in SMID-cap biotech heading into 2026 for commercial or near-commercial stage companies. As part of its 2026 outlook, Citi upgraded both Arvinas and Krystal Biotech while adding an “upside 90-day catalyst watch” on Olema Oncology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics files $500M mixed securities shelf
- Arcturus Therapeutics Announces CFO Departure and Replacement
- Arcturus Therapeutics price target lowered to $9 from $12 at Citi
- Arcturus Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Arcturus Therapeutics Earnings Call: Progress Amid Challenges